Login to Your Account

Squeezing the Bottom Line

Amgen, AstraZeneca Join Rise of Peer-to-Peer Deal

By Trista Morrison

Monday, April 16, 2012

Amgen Inc. and AstraZeneca plc's recent five-product inflammation partnership makes them the latest players in the peer-to-peer collaboration game, a business development trend that appears to be gaining traction now that the patent cliff is at hand.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription